GenSight Biologics annonce les résultats d'efficacité et de sécurité à cinq ans de la thérapie génique LUMEVOQ® à l'issue de l'étude REFLECT
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 12 2025
0mins
Should l Buy ?
Source: Businesswire
Study Results: GenSight Biologics announced positive results from a 5-year follow-up of their Phase III REFLECT study on LUMEVOQ (lenadogene nolparvovec), showing sustained improvement in visual acuity for patients with Leber Hereditary Optic Neuropathy (LHON) after a single gene therapy injection, particularly benefiting those receiving bilateral treatment.
Safety Profile: The safety profile of LUMEVOQ remained favorable, with no serious adverse events reported, and comparable outcomes between patients treated bilaterally and unilaterally, reinforcing the therapy's viability for treating this rare genetic condition.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
